EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy

Jiahui Dai, Yang Liu, Xueya Wang, Xinping Zhou, Changrui Xie, Yong Jin iD

Molecules · 08.11.2026 · 31 (21) · 4024

DOI: 10.3390/molecules31214024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 08.11.2026. Verfasst von Jiahui Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei 231200, China. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis, Antineoplastic Agents, Nanostructures. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Project of Natural Science Foundation of Anhui Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) induce target protein ubiquitination and proteasomal degradation via recruitment of E3 ubiquitin ligases, enabling event-driven intervention against “undruggable” targets, drug-resistant proteins, and non-catalytic scaffolding functions. Conventional PROTACs, however, face limitations including high molecular weight, poor solubility and membrane permeability, unfavorable pharmacokinetics, limited tissue selectivity, and the hook effect. Self-assembled Nano-PROTACs allow direct nanostructure formation from intact PROTACs, prodrugs, or functional modules, and permit spatiotemporal activation by tumor microenvironment or exogenous stimuli. This review systematically examines four assembly paradigms—carrier-free co-assembly, amphiphilic conjugates, peptide- and nucleic acid-programmed assembly, and split intracellular systems—and positions stimuli-responsiveness as a cross-architectural activation hallmark. Representative studies across cancer types are categorized to analyze how self-assembled Nano-PROTACs intervene in key oncogenic processes, with comparisons of target selectivity, activation mechanisms, degradation evidence, and antitumor efficacy. Finally, clinical translation requirements are discussed regarding structure–assembly–degradation relationships, safety, quality control, and scalable manufacturing, aiming to facilitate further research and clinical development of self-assembled Nano-PROTACs in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProteolysisAntineoplastic AgentsNanostructuresNanoparticlesHumansProteolysis Targeting ChimeraAnimals

Stichwörter der Autor:innen

cancer therapyclinical translationself-assembled Nano-PROTACsstimuli-responsivetargeted protein degradation

Substanzen

Proteolysis Targeting ChimeraAntineoplastic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Anhui Medical University, Hefei 231200, China.

ORCID-Profile: Yong Jin

Förderung

  • Key Project of Natural Science Foundation of Anhui Provincial Department of Education

Zitieren

APA

Dai, J., Liu, Y., Wang, X., Zhou, X., Xie, C., & Jin, Y. (2026). Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy. Molecules, 31(21), 4024. https://doi.org/10.3390/molecules31214024

Vancouver

Dai J, Liu Y, Wang X, Zhou X, Xie C, Jin Y. Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy. Molecules. 2026;31(21):4024. doi:10.3390/molecules31214024

BibTeX
@article{Dai2026,
  author = {Dai, Jiahui and Liu, Yang and Wang, Xueya and Zhou, Xinping and Xie, Changrui and Jin, Yong},
  title = {Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {21},
  pages = {4024},
  doi = {10.3390/molecules31214024}
}
Kostenlos starten →